Global – October 21, 2026 -- Telix is soliciting partners across five areas of radiopharmaceutical development, with deal structures ranging from licensing and co-development to strategic M&A.
Telix targets therapeutic assets with established proof of concept
In therapeutics, Telix is looking for theranostic oncology programs in urologic and neurologic cancers, other solid tumors and hematologic malignancies. Candidates must have established proof of concept. Telix says they should benefit from its fully integrated radiopharmaceutical platform and strengthen its pipeline, platform and long-term growth.
Precision medicine and medtech partnerships cover imaging, dosimetry and decision support
The precision medicine track covers developers of PET and SPECT agents and novel therapies that expand Telix's therapeutic portfolio and support a theranostic approach across oncology. The medtech track covers image-guided cancer treatment technologies: workflow enhancement, dosimetry and therapy planning, and decision-support systems.
Telix Manufacturing Solutions seeks partners in isotope technologies and large-scale formulation
Through Telix Manufacturing Solutions, the company is working to strengthen global radiopharmaceutical production. Focus areas are isotope technologies, purification, automation and large-scale formulation for diagnostic and therapeutic isotopes worldwide.
A fifth track supports early-stage research, including novel radiochemistry and chelation, new targeting agents and tumor-microenvironment approaches.
Telix pitches an integrated model spanning research to commercialization
Telix describes itself as a fully integrated radiopharmaceutical company with expertise in research, clinical development, regulatory affairs, manufacturing and commercialization. Its Business Development and Alliance Management team evaluates opportunities in confidence and builds flexible deal structures.
Among recent business development news, Telix announced collaborations to explore PSMA-PET imaging in emerging prostate cancer treatment approaches.